Johnson & Johnson’s Rybrevant, a lung cancer treatment, continues to demonstrate positive results. A new study shows that a prophylactic strategy significantly reduces infusion-related reactions, while long-term data from the MARIPOSA study reinforces Rybrevant’s effectiveness in combination with Lazcluze, improving survival and disease control compared to standard treatment.